Itır Ebru ZEMHERİ, Asıf YILDIRIM, Mehmet Cenk GÜRBÜZ, Bayram GÜNER, Turhan ÇAŞKURLU, Sıdıka Şeyma ÖZKANLI

Hyaluronidase-1 expression is not a predictor of biochemical recurrence in radical prostatectomy specimens

The purposes of this study were to evaluate the rate of biochemical recurrence among patients who underwent radical prostatectomy due to localized prostate cancer, assess the risk factors of biochemical recurrence, and investigate its relation with hyaluronidase-1 (HYAL-1). Materials and methods: We retrospectively evaluated the data of 112 patients who underwent radical retropubic prostatectomy. HYAL-1 expression was evaluated immunohistochemically and staining was graded as mild, moderate, and severe. Two blinded pathologists evaluated the specimens. The relation among preoperative pathologic findings that were detected in transrectal ultrasound (TRUS) guided biopsy, specimens of radical prostatectomy in the final stage, and biochemical recurrence rate were also evaluated. Mean follow-up time was 59.8 months (range: 20 to 92 months). Results: Tumor recurrence was detected in 29 patients. There was no relation between HYAL-1 expression and recurrence. In multivariate analysis, the percentage of tumors detected in TRUS biopsy specimens, positive surgical margin, capsular involvement, and seminal vesicle invasion detected in the final pathology were correlated with recurrence. The sensitivity, specificity, positive predictive value, and negative predictive value of HYAL-1 expression were respectively 38%, 63%, 30%, and 71%. Conclusion: HYAL-1 expression was not found to be predictive for recurrence. Further molecular markers and genetic studies are necessary to predict the biochemical recurrence after radical prostatectomy.

Anahtar Kelimeler:

Key words: Prostate, prostate cancer, recurrence, hyaluronic acid

Hyaluronidase-1 expression is not a predictor of biochemical recurrence in radical prostatectomy specimens

Keywords:

Key words: Prostate, prostate cancer, recurrence, hyaluronic acid,

PDF

___

Lipponen P, Aaltomaa S, Tammi R, Tammi M, Agren U, Kosma VM. High stromal hyaluronan is associated with poor diff erentiation and metastasis in prostate cancer. Eur J Cancer 2001; 37: 849-56.
Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johannson R et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000; 156: 529-36. 6. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998; 58: 342-7.
Hautmann SH, Lokeshwar VB, Schroeder GL, Civantos F, Duncan RC, Gnann R et al. Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. J Urol 2001; 165: 2068-74.
Lokeshwar VB, Obek C, Soloway MS. Tumor-associated hyaluronan: a new and sensitive and specifi c urine marker for bladder cancer. Cancer Res 1997; 57: 773-7. 9. Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen J, Johannson R et al. Prognostic value of hyaluronan expression in non-small-lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 2001; 95: 12-27.
Anttila MA, Tammi R, Tammi M. High levels of stromal HA predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000; 60: 150-5.
Toole BP. Proteoglycans and hyaluronan in morphogenesis and diff erentiation. In: Hey ED, editor. Cell biology of extracellular matrix, vol. 19. New York: Plenum Press; 1991. p.305-14.
Csoka A, Frost G, Stern R. Th e six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001; 2: 499-508.
Lepperdinger G, Mulleger J, Kreil G. Hyal2 - less active, but more versatile? Matrix Biol 2001; 20: 509-14.
Laurent TC, Fraser JRE. Hyaluronan. FASEB J 1992; 6: 2397- 404.
Tammi MI, Day AJ, Turley E. Hyaluronan and homeostasis: a balancing act. J Biol Chem 2002; 277: 4581-4.
Paiva P, Van Damme MP, Tellbach M, Jones RL, Jobling T, Salamonsen LA. Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. Gynecol Oncol 2005; 98: 193-202.
Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001; 276: 11922-32.
Kosaki R, Watanabe K, Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase HAS2 enhances anchorage independent growth and tumorigenicity. Cancer Res 1999; 59: 1141-5.
Liu N, Gao F, Han Z, Xu X, Underhill CB, Zhang L. Hyaluronan synthase 3 expression promotes the growth of TSU prostate cancer cells. Cancer Res 2001; 61: 5207-14.
Liu N, Lapcevich RK, Underhill CB, Han Z, Gao F, Swartz G et al. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res 2001; 61: 1022-8.
Itano N, Sawai T, Miyaishi O, Kimata K. Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res 1999; 59: 2499-504.
Hayen W, Goebler M, Kumar S, Riessen R, Nehls V. Hyaluronan stimulates tumor cell migration by modulating the fi brin fi ber architecture. J Cell Sci 1999; 112: 2241-51.
Itano N, Atsumi F, Sawai T, Yamada Y, Miyaishi O, Senga T et al. Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc Natl Acad Sci USA 2002; 99: 3609-14.
Gately CL, Muul LM, Greenwood MA, Papazoglou S, Dick SJ, Kornblith PL et al. In vitro studies on the cell mediated immune response to human brain tumors: leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack. J Immunol 1984; 133: 3387-95.
Lokeshwar VB, Lokeshwar BL, Pham HT, Block NL. Association of hyaluronidase, a matrix-degrading enzyme with prostate cancer progression. Cancer Res 1996; 56: 651-7.
Bertrand P, Girard N, Duval C, d’Anjou J, Chauzy C, Menard J et al. Increased hyaluronidase levels in breast tumor metastases. Int J Cancer 1997; 77: 327-31.
Lokeshwar VB, Young MJ, Goudarz IG, Iida N, Yudin AI, Cherr GN et al. Identifi cation of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Cancer Res 1999; 59: 4464-70.
Gomez CS, Gomez P, Knapp J, Jorda M, Soloway MS, Lokeshwar, VB. Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. J Urol 2009; 182: 1350-6.
Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC et al. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase for prostate cancer. Cancer Res 2003; 63: 2638-44.
Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44V6 and microvessel density for prostate cancer. Int J Cancer 2004; 112: 121-9.
Ertoy Baydar D, Özen H, Saraçbaşı O, Karabulut E. PTEN expression in primary prostate carcinoma in Turkish patients. Turk J Med Sci 2008; 38: 387-97.
Kosova B, Bozok Çetintaş V, Çal AÇ, Tetik A, Özel R, Aktan Ç et al. N-acetyltransferase 2 gene polymorphisms and susceptibility to prostate cancer: a pilot study in the Turkish population. Turk J Med Sci 2010; 40: 629-36.
Bektaş S, Bahadır B, Doğan Gür B, Kertiş G, Özdamar ŞO. Th e relation between gleason score, and nuclear size and shape factors in prostatic adenocarcinoma. Turk J Med Sci 2009; 39: 381-7.